Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clofarabine in Recurrent or Refractory Langerhans Cell Histiocytosis and LCH-related Disorders
NCT02425904Phase 2Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- May 2015
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of clofarabine in Langerhans cell histiocytosis (LCH), Rosai-Dorfman disease (RDD), Erdheim-Chester disease (ECD), sponsored by Dana-Farber Cancer Institute. Started May 2015; status: active, not recruiting.
02
Drugs
clofarabine
03
Conditions
Langerhans cell histiocytosis (LCH)Rosai-Dorfman disease (RDD)Erdheim-Chester disease (ECD)
Beyond the preview
Go deeper on NCT02425904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02425904.